Patent · US Active

FGF-9 variants and methods for use thereof

US8609823B2 · kind B2 · utility

0Cited by

32References

13Claims

0Family size

Assignee

PROCHON BIOTECH LTD. · IL

Inventors

Oren Bogin · Mazkeret Batya, IL
Avner Yayon · Afula, IL

Key dates

Filing date	Jan 11, 2012
Grant date	Dec 17, 2013
Priority date	—
Expiry date	Jan 28, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2506/1346
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.